Skip to main content
. 2021 Apr 23;10(5):513. doi: 10.3390/pathogens10050513

Figure 5.

Figure 5

Comparison of PrP glycoforms between VPSPr and sCJD by antibodies with glycan-controlled epitopes. PrP from brain homogenates of VPSPr, sCJD and non-CJD was treated without (A,B) or with PNGase F (C,D) prior to western blot analysis probing with antibody V14 (A,C) or Bar209 (B,D) that recognizes either PrP mono-glycosylated at residue 181 (Mono181) or residue 197 (Mono197), respectively, while both of them also recognize unglycosylated PrP species. FL: full-length PrP; Mono181-C1: truncated PrP C1 fragment glycosylated at residue 181; Mono197-C1: truncated PrP C1 fragment glycosylated at residue 197; C1: C-terminally truncated PrP fragment migrating at ~18 kDa; C2: C-terminally truncated PrP fragment migrating at ~20 kDa. The red dotted lines are used as a reference for comparison of the top bands in each panel. The red arrows indicate additional band between FL and C2 in sCJD in panels (C) and (D). The red arrow head indicates the doublets of FL bands in panel (D).